Biogen

2 Stories

Sofa-Treating Chemical Reborn as Major MS Drug

Analyst predicts $1.7B in Tecfidera sales by 2015

(Newser) - As a sofa-treating agent, dimethyl fumarate gave people blisters and rashes, but now it's getting a second chance—as a much ballyhooed multiple sclerosis drug called Tecfidera, whose sales could be enormous. Among doctors, there's "a strong consensus that Tecfidera offers a more favorable clinical profile than... More »

Company Pulls Drug for Lou Gehrig's Disease

Biogen ends development after it fails drug trial

(Newser) - An experimental drug that showed promise of becoming the first effective treatment for Lou Gehrig’s Disease is being pulled by its manufacturer because it performed miserably in a major drug trial. Biogen says its drug, dexpramipexole, did nothing to improve the condition of patients or extend their lives, reports... More »

2 Stories

AROUND THE WEB